Current concepts on GUILLAIN-Barr&eacute; syndrome

Lisnic Vitalie; Gavriliuc Eugen; Odainic Olesea; Chetrari Larisa; Sangheli Marina; Pleşca Svetlana

Articolul precedent

Articolul urmator

482

Ultima descărcare din IBN:
2024-06-09 20:34

Căutarea după subiecte
similare conform CZU

616.833.17-08 (2)

Neurology. Neuropathology. Nervous system (985)

SM ISO690:2012

LISNIC, Vitalie, GAVRILIUC, Eugen, ODAINIC, Olesea, CHETRARI, Larisa, SANGHELI, Marina, PLEŞCA, Svetlana. Current concepts on GUILLAIN-Barré syndrome. In: European teaching course on neurorehabilitation, 1-3 iunie 2016, Cluj-Napoca. Cluj Napoca, Romania: Institute for Neurological Research and Diagnostic, 2016, Ediția a 6-a, pp. 39-40. ISSN 2501-7039; ISSN-L 2501-7039.

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

European teaching course on neurorehabilitation
Ediția a 6-a, 2016

Sesiunea "European teaching course on neurorehabilitation"
Cluj-Napoca, Romania, 1-3 iunie 2016

Current concepts on GUILLAIN-Barré syndrome

CZU: 616.833.17-08

Pag. 39-40

Lisnic Vitalie, Gavriliuc Eugen, Odainic Olesea, Chetrari Larisa, Sangheli Marina, Pleşca Svetlana

”Nicolae Testemițanu” State University of Medicine and Pharmacy

Proiecte:

Menționat în lucrare: 15.817.04.50A Abordarea multidimensională a patologiei neuromusculare şi spinale. Studiu clinic, neuroepidemiologic şi neurofiziologic cu elaborarea strategiilor terapeutice

Disponibil în IBN: 23 noiembrie 2021

Descarcă PDF

Teza

This year we mark the centenary since the description of Guillain-Barré
syndrome (GBS). At the same time the recognition of its numerous variants and
subtypes is part of its continuously evolving and fascinating history. GBS is the
most frequent cause of a subacute neuromuscular palsy. Its incidence is 1,2-
1,8/100.000. In the countries of the EU there are about 7000 cases annually. In
spite of the relative low lethality – 3-5%, the most of the patients are severely
affected, 25% require artificial ventilation and 20% are not able to walk at half a
year after onset. Most of the patients (two thirds) die due to complications at the
rehabilitation stage. In about 10% cases GBS have a recurrent course. Additional

IVIG course is under investigation for these patients. In other 5% cases chronic
inflammatory demyelinating polyneuropathy could start as GBS. Antiganglioside
antibodies are associated with a more severe course; their concentration is higher
at the onset of weakness. Pain is persistent during the whole disease evolution;
in 40% patients is manifested before motor involvement. In 2011 were published
the new Brighton diagnostic criteria (Sejvar et al.), validated in the Netherlands,
India. IVIG and plasma exchange remain the main treatment in GBS, but as well
the general treatment play an essential role. A special attention should be paid to
the management of pain and fatigability. There are proposed systems to establish
prognosis in GBS as EGRIS (Erasmus GBS Respiratory Insufficiency Score) and
IGOS (International GBS Outcome Study). Ongoing trial of Eculizumab could bring
promising results.

Crossref XML Export

<?xml version='1.0' encoding='utf-8'?>
<doi_batch version='4.3.7' xmlns='http://www.crossref.org/schema/4.3.7' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xsi:schemaLocation='http://www.crossref.org/schema/4.3.7 http://www.crossref.org/schema/deposit/crossref4.3.7.xsd'>
<head>
<doi_batch_id>ibn-143085</doi_batch_id>
<timestamp>1718788481</timestamp>
<depositor>
<depositor_name>Information Society Development Instiute, Republic of Moldova</depositor_name>
<email_address>[email protected]</email_address>
</depositor>
</head>
<body>
<collection>
<collection_metadata>
<full_title>European teaching course on neurorehabilitation</full_title>
<issn media_type='print'>2501-7039; ISSN-L 2501-7039</issn>
</collection_metadata>
<collection_issue>
<publication_date media_type='print'>
<year>2016</year>
</publication_date>
</collection_issue>
<collection_article publication_type='full_text'><titles>
<title>Current concepts on GUILLAIN-Barr&eacute; syndrome</title>
</titles>
<contributors>
<person_name sequence='first' contributor_role='author'>
<given_name>Vitalie</given_name>
<surname>Lisnic</surname>
</person_name>
<person_name sequence='additional' contributor_role='author'>
<given_name>Eugen</given_name>
<surname>Gavriliuc</surname>
</person_name>
<person_name sequence='additional' contributor_role='author'>
<given_name>Olesea</given_name>
<surname>Odainic</surname>
</person_name>
<person_name sequence='additional' contributor_role='author'>
<given_name>Larisa</given_name>
<surname>Chetrari</surname>
</person_name>
<person_name sequence='additional' contributor_role='author'>
<given_name>Marina</given_name>
<surname>Sangheli</surname>
</person_name>
<person_name sequence='additional' contributor_role='author'>
<given_name>Svetlana</given_name>
<surname>Pleşca</surname>
</person_name>
</contributors>
<publication_date media_type='print'>
<year>2016</year>
</publication_date>
<pages>
<first_page>39</first_page>
<last_page>40</last_page>
</pages>
</collection_article>
</collection>
</body>
</doi_batch>